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Conclusions: It can be concluded that
all cancer cells tested have higher telo-
merase expression and activity, as com-
pared to normal cells. The high expression
and activity of telomerase in cancer cells
can be explained by amplified TERT gene.
Therefore telomerase can be a good
cancer marker provided quantitative
analysis is carried out. Grant support: The
work was sponsored by KSN grants No
4P05B 072 17 and 6P05E 102 20.
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Background: The erbS family of proto-
oncogenes (erbS-1, erbS-2, erbS-3, erbS-
4) and their receptors play an important
role in normal cell growth and neoplastic
transformation. Literature data indicate
that some abnormalities of erbS oncogene
play an important role in breast cancer
development, correlate with tumor aggre-
ssiveness and with worse clinical outcome.
Therefore, these abnormalities may poten-
tially have prognostic and therapeutic
relevance. Aim of the stUdy: To determine
the number of gene copies within erbS
oncogene family in breast cancer. The
relationship of abnormalities /CAln in the
dinucleotides and the loss of hetero-
zygosity (LOH) in erbS-1 were analyzed in
. relation to clinical and pathological fea-
tures of the tumors and to chemotherapy
response.
Matherials and methods: StUdy
subjects included 50 chemotherapy naive
LABC (any T, N2, any N, T4) patients
(pts). All pts received induction chemothe-
rapy. Tumor measurement was performed
after each cycle and at the completion
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of induction chemotherapy. Double diffe-
rential PCR (ddPCR) was used for de-
tection of erbS oncogene family abnor-
malities (gene amplification/deletion).
Microsatellite polymorphism of erbS-1 was
examined by PCR with fluorescently
labeled primers, followed by capillary
electrophoresis and quantitative analysis
of PCR product with GeneScanTM sys-
tem, using automated ASI PRSM 310.
Results: Amplifications of erbB-1, erbB-
2, erbB-3, erbB-4 (defined as AGCN value
of > 1.6) were detected in 5.9%, 26.5%,
2.9% and 2.9% of examined cases,
respectively. Deletions, defined as AGCN
value of < 0.4, accompanied only erbS-1
amplification and occurred in 26.5% of all
cases. There was a polymorphic simple
sequence repeat region of 12-20 CA
detected in the first intron of erbS-1.
Homozygotes comprised 31 % of the exa-
mined group. The majority of homozygous
pts revealed 14/14 CA repeat combination.
LOH (most frequently affecting shorter
allele) was determined in breast cancer
heterozygotes and occurred in 50%
of cases. Correlations between these fin-
dings and clinical outcomes will be pre-
sented.
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Objectives: The purpose of the study
was to evaluate the frequency of abnormal
DNA content in squamous cancer cells
(SCLC) and analyze its correlation with
late survival rates after surgical treatment.
Many previous studies included attempts
to associate DNA quantification with
prognosis for lung cancer. However, there
is still considerable divergence of opinion
about its prognostic value.
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